The Flanders Interuniversity Institute for Biotechnology (VIB) and Ghent University have started up a new biopharmaceutical company named Peakadilly nv. Peakadilly will develop and market a new generation of molecular diagnostics − so-called protein bio-markers − using innovative proteomics technology developed by the research group under the direction of Joël Vandekerckhove. The markers can be used in the development of medicines, making the process much more efficient, effective and economical. The bio-markers will also enable doctors to detect diseases sooner and, because many medicines work effectively only with a limited group of patients, doctors will also be able to verify whether a particular medicine will work for certain patients. Peakadilly will be led by Koen Kas, who has been closely involved in the development of the technology platform.
Health care tailored to the patient
Today, it takes an average of 800 million euro and about 12 years to develop a new drug. Among other things, the time-consuming and expensive clinical studies test the safety and effectiveness of a potential medicine. Frequently, the studies indicate that the drug is not really effective at all, or only for a small number of patients. At present, nothing exists for measuring whether a candidate drug is truly effective during development. Bio-markers can bridge this gap and thus substantially lower the development costs and time.
Rudy Dekesyer | alfa
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy